Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Brokerages Expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to Announce -$0.15 EPS

researchsnappy by researchsnappy
December 8, 2019
in Healthcare Research
0
Strs Ohio Has $625,000 Stake in Collegium Pharmaceutical Inc (NASDAQ:COLL)
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Collegium Pharmaceutical logoAnalysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is ($0.03) and the lowest is ($0.21). Collegium Pharmaceutical reported earnings of ($0.10) per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is expected to announce its next earnings results on Wednesday, February 26th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of ($0.64) per share for the current financial year, with EPS estimates ranging from ($0.82) to ($0.25). For the next financial year, analysts forecast that the firm will report earnings of $0.19 per share, with EPS estimates ranging from ($0.31) to $0.94. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). Collegium Pharmaceutical had a negative net margin of 3.86% and a negative return on equity of 13.14%. The business had revenue of $72.94 million during the quarter, compared to analyst estimates of $74.32 million. During the same quarter last year, the company posted ($0.50) earnings per share. The company’s revenue was up 3.9% on a year-over-year basis.

Several equities research analysts recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of Collegium Pharmaceutical from $33.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, October 30th. SunTrust Banks upped their price objective on shares of Collegium Pharmaceutical to $22.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. BidaskClub raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. Finally, Jefferies Financial Group upped their price objective on shares of Collegium Pharmaceutical from $26.00 to $36.00 in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $24.57.

COLL traded down $0.18 on Friday, hitting $18.11. 410,300 shares of the stock were exchanged, compared to its average volume of 380,659. Collegium Pharmaceutical has a 12 month low of $10.01 and a 12 month high of $19.99. The business has a 50-day moving average of $12.93 and a two-hundred day moving average of $12.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.20. The firm has a market capitalization of $641.71 million, a price-to-earnings ratio of -15.21 and a beta of 0.52.

In other news, Director David Hirsch sold 25,000 shares of the stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $19.33, for a total value of $483,250.00. Following the completion of the transaction, the director now owns 17,117 shares of the company’s stock, valued at $330,871.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph Ciaffoni sold 64,821 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $18.77, for a total transaction of $1,216,690.17. Following the completion of the transaction, the chief executive officer now directly owns 242,276 shares of the company’s stock, valued at approximately $4,547,520.52. The disclosure for this sale can be found here. Insiders sold 111,927 shares of company stock valued at $1,957,475 in the last three months. Company insiders own 8.08% of the company’s stock.

Several hedge funds have recently bought and sold shares of COLL. Cortina Asset Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 81.0% in the second quarter. Cortina Asset Management LLC now owns 509,701 shares of the specialty pharmaceutical company’s stock worth $6,703,000 after acquiring an additional 228,035 shares during the last quarter. First Quadrant L P CA lifted its holdings in shares of Collegium Pharmaceutical by 87.2% in the second quarter. First Quadrant L P CA now owns 4,484 shares of the specialty pharmaceutical company’s stock worth $59,000 after acquiring an additional 2,089 shares during the last quarter. Strs Ohio raised its holdings in Collegium Pharmaceutical by 24.9% in the 2nd quarter. Strs Ohio now owns 49,700 shares of the specialty pharmaceutical company’s stock valued at $653,000 after buying an additional 9,900 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Collegium Pharmaceutical by 19.1% in the 2nd quarter. Janus Henderson Group PLC now owns 4,323,555 shares of the specialty pharmaceutical company’s stock valued at $56,855,000 after buying an additional 693,812 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in Collegium Pharmaceutical by 63.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 21,600 shares of the specialty pharmaceutical company’s stock valued at $286,000 after buying an additional 8,400 shares during the last quarter. 91.02% of the stock is owned by hedge funds and other institutional investors.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Read More: What is the G-20?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)



Receive News & Ratings for Collegium Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Collegium Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

A Hands-On Guide To Regression With Fast.ai

Next Post

New, Large Funds From Sequoia And Hillhouse Chase The Next China Opportunities, Politics Aside

Next Post
New, Large Funds From Sequoia And Hillhouse Chase The Next China Opportunities, Politics Aside

New, Large Funds From Sequoia And Hillhouse Chase The Next China Opportunities, Politics Aside

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Healthcare Research
  • Investment Research

PLMA Live! Presents a Week of Top Speakers, Video Programming for Private Label Week

How 2020 Forced Innovation Across Sectors

Earn Extra Money by Joining Online Focus Groups | Pennyhoarder

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2020 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2020 researchsnappy.com